Greenwich Lifesciences Inc (GLSI)

$17.44

+2.68

(+18.16%)

Market is closed - opens 7 PM, 18 Jun 2024

Insights on Greenwich Lifesciences Inc

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 74.1% return, outperforming this stock by 14.1%

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 241.2% return, outperforming this stock by 293.8%

Performance

  • $15.22
    $18.00
    $17.44
    downward going graph

    12.73%

    Downside

    Day's Volatility :15.44%

    Upside

    3.11%

    downward going graph
  • $7.58
    $21.44
    $17.44
    downward going graph

    56.54%

    Downside

    52 Weeks Volatility :64.65%

    Upside

    18.66%

    downward going graph

Returns

PeriodGreenwich Lifesciences IncSector (Health Care)Index (Russel 2000)
3 Months
2.41%
0.6%
0.0%
6 Months
71.65%
8.9%
0.0%
1 Year
60.89%
10.2%
0.0%
3 Years
-52.57%
17.8%
-20.9%

Highlights

Market Capitalization
190.1M
Book Value
$0.4
Earnings Per Share (EPS)
-0.71
Wall Street Target Price
36.0
Profit Margin
0.0%
Operating Margin TTM
0.0%
Return On Assets TTM
-69.02%
Return On Equity TTM
-109.97%
Revenue TTM
0.0
Revenue Per Share TTM
0.0
Quarterly Revenue Growth YOY
0.0%
Gross Profit TTM
0.0
EBITDA
-9.6M
Diluted Eps TTM
-0.71
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-0.75
EPS Estimate Next Year
-0.7
EPS Estimate Current Quarter
-0.2
EPS Estimate Next Quarter
-0.2

Analyst Recommendation

Buy
    85%Buy
    14%Hold
    0
    0%Sell
Based on 7 Wall street analysts offering stock ratings for Greenwich Lifesciences Inc(by analysts ranked 0 to 5 stars)
Based on 7 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
6
6
6
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 106.42%

Current $17.44
Target $36.00

Technicals Summary

Sell

Neutral

Buy

Greenwich Lifesciences Inc is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Greenwich Lifesciences Inc
Greenwich Lifesciences Inc
33.33%
71.65%
60.89%
-52.57%
248.8%
Moderna, Inc.
Moderna, Inc.
-2.21%
61.44%
11.0%
-30.77%
776.11%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
5.88%
22.86%
33.81%
94.34%
240.92%
Novo Nordisk A/s
Novo Nordisk A/s
5.61%
41.82%
73.65%
241.2%
437.92%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
6.24%
17.06%
38.23%
152.16%
166.21%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Greenwich Lifesciences Inc
Greenwich Lifesciences Inc
NA
NA
NA
-0.75
-1.1
-0.69
NA
0.4
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-6.72
-0.38
-0.16
NA
33.47
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
30.58
30.58
1.46
44.13
0.15
0.08
NA
250.15
Novo Nordisk A/s
Novo Nordisk A/s
49.48
49.48
2.36
3.47
1.0
0.25
0.01
22.18
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
31.16
31.16
0.53
17.09
0.24
0.13
NA
71.8
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Greenwich Lifesciences Inc
Greenwich Lifesciences Inc
Buy
$190.1M
248.8%
NA
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$53.7B
776.11%
24.73
-115.82%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$114.2B
240.92%
30.58
29.45%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$636.1B
437.92%
49.48
36.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$124.1B
166.21%
31.16
39.46%

Institutional Holdings

  • Vanguard Group Inc

    1.73%
  • Millennium Management LLC

    0.50%
  • BlackRock Inc

    0.44%
  • Ameriprise Financial Inc

    0.42%
  • Geode Capital Management, LLC

    0.36%
  • Renaissance Technologies Corp

    0.28%

Company Information

Organization
Greenwich Lifesciences Inc
Employees
3
CEO
Mr. Snehal S. Patel
Industry
Health Technology

FAQs